



Tuesday 8th & Wednesday 9th November 2022

Conference Day 1 - Tuesday, 8th November

8:00am Registration, Breakfast and Networking

9:00am Chair's Opening Remarks

Danny Kim, Chief of Staff, [WELT](#)

9:10am Keynote Discussion: Welcome to DTx Asia - Let's Talk Digital Therapeutics

- A sitdown with some of the world leaders in digital therapeutics, discussing the market opportunities within Asian healthcare
- An introduction into DTx - How do we define true digital therapeutics?
- Establishing the difference between digital health solutions and digital therapeutics
- How do DTx companies plan to innovate healthcare in the APAC?

Danny Kim, Chief of Staff, [WELT](#)

Megan Coder, Chief Policy Officer, [Digital Therapeutics Alliance](#)

Abhishek Shah, CEO & Co-Founder, [Wellthy Therapeutics](#)

Sarah Jackson, Director, Business Development & Alliance Management, [Click Therapeutics](#)

9:50am Keynote Panel Discussion: Where is DTx today? An Overview of the Evolving Market Landscape, Strategies, and Opportunities for DTx in Asia

- Would digital health tools be a part of the discussion in Asia without the impacts of Covid-19?
- What markets in Asia are beginning to adopt DTx?
- Where are the current regulatory barriers and opportunities in the different markets for digital health?
- What changes need to be made at the regulatory level to streamline digital health adoption?
- What are the other key challenges facing DTx in Asia?
- How are we going to tackle these moving forward?
- What do we expect the future of digital health in the APAC to look like?
- Which countries are next?

Arbinder Singal, Co-Founder & CEO, [Fitterfly](#)

Christopher Wasden, Chief Strategy Officer, [Twill](#)
Kaishen Chen, CEO & Founder, [CinoCore](#)
Louis Payet, Head of Mergers and Acquisitions, [Zuellig Pharma](#)

10.30am Morning Refreshments & Networking

Commercialisation and Reimbursement

11:00am Presentation - How to Innovate Digital Therapeutic Business Models within the Asian Healthcare Market?

- How do commercial models for out of pocket paying differ from healthcare insurance?
- Which regions in the APAC should DTx companies target for out-of-pocket payment of digital health tools?
- Can you scale digital health tools by solely targeting top end clinics?
- Is there greater scope for scaling DTx in Asia through accessing this market?

Siva Nadarajah, Co-Founder & President, [JOGO Health](#)

11:25am Presentation – Launching and Scaling DTx Products in the United States

Tremendous tailwinds have created an exciting environment for Digital Therapeutics in the United States, ranging from emerging business models and reimbursement pathways, as well as increasing clarity from the US FDA on how it will regulate DTx solutions. As a result, DTx companies are now gaining traction and interest from all members of the ecosystem, including providers, payers, employers, pharma as well as other digital health and telehealth companies.

- Current headwinds and tailwinds facing DTx companies in the United States
- Market activity among various buyers (providers, payers, employers, pharma) as it relates to DTx solutions
- Key considerations on how to assess whether your DTx solution will succeed in the US

Kamal Jethwani, Co-Founder & CEO, [Decimal.health](#)

11:50am Panel Discussion: Exploring How DTx Companies Aim to Tackle the Fragmented Reimbursement Landscape in Asia

- What commercial models are companies using to tackle the different markets in Asia?
- In which countries are we seeing the most success of DTx integration and why?
- Should we implement similar strategies from Europe and the US in Asia? What should we transfer over?
- Can you integrate digital health into lower resourced countries?

- Can we one day speak to Asia as a centralized unity?
- How can DTx companies from Europe and the US scale their products in Asia? What are the guidelines?
- Is Asia ready for DTx?

Teo Son, Chief Operating Officer, [Olive Union](#)

Ihsan Almarzooqi, Co-Founder & Managing Director, [GluCare.Health](#)

Mayank Singh, Founder & CEO, [Impute Inc.](#)

12:30pm

Lunch & Networking

Regulatory

1:45pm Presentation: A Breakdown of the Japanese Government's Current Work on Creating SaMD Frameworks

- A look into how Japan are establishing regulatory guidelines to promote digital health adoption
- How is regulation on digital health in Japan changing?
- What can other countries in the APAC learn from the Japanese government's work?

Takeshi Fujiwara, METI: Counselor, [Japanese Ministry of Economy, Trade and Industry, Healthcare Industry Division Medical and Welfare Equipment Industry Office](#)

2:10pm Presentation: Growing Japanese DTx Start-ups from a VC Perspective. Impact of Regulation, Reimbursement and Future Trends

- Trends of DTx startups and start-up investment in Japan: past and future
- The impact of Japan's reimbursement system on business
- Effect of digital health regulation on start-ups
- How can foreign startups enter the Japanese market?

Katsuya Hashizume, Executive Officer, [Beyond Next Ventures](#)

2:35pm Panel Discussion: Breaking Down the Roadmap for Regulatory Approval of DTx in the APAC Regions

- Which countries are beginning to adopt regulatory guidelines for digital health products?
- Insight into how regulatory approval in Europe and the US can translate to some Asian countries
- How do these countries differ from one another?
- Why are some countries in the APAC still hesitant to integrate DTx into healthcare? How can these issues be addressed?

Moderator: **Martin Culjat**, SVP, Regulatory Innovation & Digital Medicine, [EVERSANA](#)
Setiaji Setiaji, Chief of Digital Transformation Office, [Ministry of Health of the Republic of Indonesia](#)
Bunty Kundani, Head of Regulatory Affairs, [Qure.ai](#)
Neeraj Mehta, Digital Health Expert, [Ministry of Health, Government of India](#)
Brian Suh, Head of Government Affairs, [Varian Korea, a Siemens Healthineers Company](#)

3:20pm **Afternoon Refreshments and Networking**

3:50pm Presentation: Pathway to the Market: Clinical and Business Development in Japan

- The Japanese DTx market and landscape, opportunities for DTx companies
- Critical Components for the clinical evidence generation to successfully receive reimbursement approval
- Partnerships with key stakeholders in the Japanese market

Tomoyuki Tanigawa, Chief Medical Officer, [CureApp](#)

4:15pm Fireside Chat: Bridging the Gap Between Pharma and DTx: A Look into How DTx are Partnering With Pharmaceutical Companies in Asia

- A look into the process of partnering with pharma companies in the APAC
- Where do you start?
- What criteria is pharma looking for in DTx companies to partner?
- What are the fundamental differences in value drivers between cultures?
- How can digital therapeutic companies bring value to pharmaceutical companies?
- What hurdles have these partnerships come across? How can others avoid these moving forward?
- Moving forward, how can DTx companies approach pharma?

Sean Kang, CEO, [WELT](#)

Sohyun Kwon, Senior Managing Director, [Handok](#)

4:50pm Chairs Closing Remarks of Day 1.

Danny Kim, Chief of Staff, [WELT](#)

5:00pm End of DTx Asia Day 1

Conference Day 2 - Wednesday, 9th November

8:00am Registration, Breakfast and Networking

9:00am Chair's Opening Remarks

Abhishek Shah, Co-Founder & CEO, [Wellthy Therapeutics](#)

Adoption

9:15am Keynote Presentation: How Digital Therapeutics Will Reimagine Patient Care?

- In this book, we speak to innovation and business leaders from all corners of the healthcare universe who are involved in designing and building tomorrow's DTx.
- Researching clinicians, researchers, engineers, patients, start-up founders, and corporate executives.
- What did we find?

Yoann Sapanel, Head, Health Innovation, [Institute for Digital Medicine](#)

9:40 Panel Discussion: A Time for Change: How Does the Industry Plan to Successfully Integrate DTx into Healthcare?

- What are the key challenges holding back adoption of DTx in the APAC?
- How does this differ from Europe and the US?
- In which countries are we seeing higher adoption of DTx?
- Are physicians less willing to adopt digital health tools in some Asian countries? If so, why?
- What's it going to take for us to make digital health a reality?

Bechara Saab, CEO & Chief Scientist, [Mobio Interactive](#)

Jason Goh, Director of Medical Services, [Monash Health](#)

Haisung Lee, Vice President, Head of Digital & BioHealth, [KT](#)

Mary-Beth Brinson, Chief Medical Officer / Interim CEO, [TALi](#)

10.40am

Morning Refreshments and Networking

11:20am Presentation: 'The Future of Digital Health Isn't Digital, it's Human'

- Harnessing the power of machines to humanize healthcare and drive superior outcomes

Ali Hashemi, Co-Founder & Chairman, [GluCare.Health](#)

11:45am Presentation: Evaluate a Multi-Domain TaiChi Digital Therapy (Taichi-DTx) for Long COVID Symptoms in a Real World Environment

Tim Shi, Founder & Executive Director, [Global MD](#)

12:10pm Panel Discussion: Increasing User Awareness and Patient Engagement - Bringing DTx to Light

- How are government bodies acting to increase awareness of DTx in Asia?
- What educational models can companies bring from the US and Europe to Asia?
- What steps can governments take to help put DTx on the consumers radar?
- How will cultural differences throughout APAC regions impact education programs for digital health?
- Once awareness of DTx is established, how are companies combating retention of digital health products?
- What can we do to ensure in 5 years time that DTx is a staple within the APAC healthcare systems?

Monika Mehta, Co-Founder & CEO, [Zealth - AI](#)

Smriti Arora, Disease Area Lead, Integrated Insights, [Novartis](#)

Sharon Chan, Head of JLABS Asia Pacific, [Johnson & Johnson](#)

Agata Blasiak, Head of Digital Health Innovation, [The N.1 Institute for Health](#)

12:50pm

Lunch and Networking

2:00pm Presentation: Pharma's Digital Health Strategy - Making Patients Smile

- Daiichi-Sankyo's Digital Health strategy and Total Care concept.
- What pharma looks for in DTx and Digital Health companies?

Yo Hashimoto, Tech Lead & Project Manager, [Daiichi Sankyo](#)

2:15pm Presentation & Discussion - The New Era of Addiction in Korean Digital Therapeutics

- Clinical practices about Addiction such as Alcohol and Nicotine
- Digital therapeutics & conventional treatment for addiction
- Cognitive Behavioral Therapy & Digital Biomarker

Dai-Jin Kim, CEO | President, [Digital Pharm | The Catholic Univ. of Korea Catholic Information Institute](#)

Haisung Lee, Vice President, Head of Digital & BioHealth, [KT](#)

2:40pm Panel Discussion - How JLABS is Working With Digital Therapeutics Start-ups in the APAC to Innovate Healthcare

- Raise awareness of the role of start-ups on how Johnson & Johnson Innovation accelerates innovation in the Asia market.
- Share best practices from JJI & JLABS' global network, including adapting and implementing successful models between JLABS facilities, overcoming regional barriers and cultural differences to drive innovation, growing and retaining our consumer base, etc.
- Engage other stakeholders within the DTx and healthcare ecosystem to broaden JJI & JLABS exposure, as well as JLABS resident companies.

Moderator: **Sharon Chan**, Head of JLABS Asia Pacific, [Johnson & Johnson](#)

More Speakers TBA

3.30pm Morning Refreshments and Networking

What's New in Asian Digital Therapeutics?

4:00pm Presentation: Developing VR Digital Therapeutics for Depression: Patient Centered Active Learning Treatment

- Targeting ruminations: Therapeutic approaches based on 3rd generation CBT.
- Patient engagement and data-driven approaches including digital biomarkers.
- From Japan to Asia: Universal design and localization in practice.

Masayo Matsumura, CEO, [Bipsee](#)

4:25pm Presentation: Innovating the Standard of Care Through Digital Monitoring Solutions for Chronic Thyroid Dysfunction and Thyroid Eye Disease

- Patient journeys for thyroid dysfunction and thyroid eye disease
- Digital biomarkers for thyroid dysfunction and thyroid eye disease
- Innovating standard of care through novel digital monitoring solutions

Jaemy Park, CEO, [Thyroscope](#)

4:50pm Presentation: The Future of Digital Therapeutics and Hearing

- Software-based medicine for hearing loss related treatments.
- How is regulation on hearing digital health evolving?

- What will it take to make hearing digital therapeutics a reality?
- How hearing digital therapeutics will improve the clinical industry?

Teo Son, Chief Operating Officer, [Olive Union](#)

5:15pm Chairs Closing Remarks of Day 2.

Abhishek Shah, Co-Founder & CEO, [Wellthy Therapeutics](#)

5:30pm End of DTx Asia